ILCN Multidisciplinary Forum: Molecular Mysteries

World Conference on Lung Cancer 2020 Landing Page Banner Image

Each month ILCN organizes discussions on molecular mysteries in Lung Cancer. The series focuses on real-life cases and features conversations with the patients and multidisciplinary teams involved in their care.

EGFR Web Page

Understanding Treatment Options and Resistance in EGFR-positive NSCLC

Unfortunately, the inevitability of therapeutic resistance is always looming for patients with EGFR-mutated lung cancer, regardless of PD-1/PD-L1 status. Dr. Karen Reckamp—together with Drs. Ibiaya Dagogo-Jack, Ticiana Leal, and Daniel Tan, as well as patient advocate Sarah Christ—talks through a patient case, exploring all facets of the care continuum for this population. 

ALK Web Page

ALK Pioneers and Progress

ALK research and therapy has evolved substantially since the original PROFILE 1001 study, which first evaluated crizotinib for patients with ALK-rearranged NSCLC. Patient advocate and ALK-positive survivor of more than 15 years, Linnea Olsen, was the fourth person in the world to go on that trial. 

ILCN Molecular Challenges

Different Tests Different Drivers: The Power of Collaboration to Solve a Molecular Mystery

When the initial molecular report suggested a ROS1 rearrangement, crizotinib was started in expectation of a typically great response. However, when the first on-treatment scan showed an increase in the size of the lung cancer it became obvious that this case was far from typical.

Image
IASLC Logo
Read IASLC General Disclaimer